Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Emerging Trends and Growth Drivers Through 2029 | Reach USD $15.09 Billion
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Today And What Is Its Future Size?
The market size for sodium glucose cotransporter 2 (sglt2) inhibitors has seen a robust expansion in the past few years. The market is projected to surge from $10.17 billion in 2024 to $10.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.8%. The historic growth is ascribed to triumphs in the early phase of clinical trials, surge in regulatory authorizations, escalation in the rate of diabetes detections, and the growing demand for pioneering diabetes therapies.
Strong expansion is predicted for the sodium glucose cotransporter 2 (sglt2) inhibitors market in the upcoming years, with an anticipated value of $15.09 billion in 2029. The expected compound annual growth rate (CAGR) stands at an impressive 8.3%. The growth can be explained by several factors, namely the increasing incidence of diabetes, the rise of obesity, a broader understanding of diabetes management, and the treatment applications widening to include heart and kidney disease. The forecast period is also set to experience major trends such as the application of combination therapies, the adoption of personalized medicine strategies, advancements in technology, and conventional drug development.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
What External And Internal Drivers Are Influencing The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The surge in diabetes cases is anticipated to fuel the expansion of the sodium glucose cotransporter 2 (SGLT2) inhibitor market in the future. Diabetes is a collection of metabolic diseases marked by elevated blood sugar levels due to problems with insulin production, insulin function, or both. The escalation in diabetes incidences can be linked to elements like urbanization, stress, environmental contamination, and inadequate healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors, which reduce blood sugar levels by blocking glucose absorption in the kidneys and prompting its expulsion through urine, are used in diabetes management. These inhibitors also provide cardiovascular and renal advantages, making them a substantial selection for controlling diabetes and its related ailments. For example, the Australian Bureau of Statistics reported in December 2023 that in 2022, approximately 5.3% of Australians, corresponding to around 1.3 million individuals, had been diagnosed with diabetes, with males (5.8%) and females (4.9%) witnessing similar rates. The incidence of diabetes has been progressively increasing, particularly in older age groups, impacting 18.7% of those aged 75 and above. Type 2 diabetes is the most prevalent variant, making up 87.6% of total cases. Factors like birth overseas, residing in disadvantaged areas, and disabilities are associated with escalated diabetes rates. Consequently, the surge in diabetes cases is facilitating the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
How Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Categorized Across Applications And Types?
The sodium glucose cotransporter 2 (sglt2) inhibitorsmarket covered in this report is segmented –
1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
2) By Route Of Administration: Oral Route; Other Route Of Administration
3) By End User: Hospitals; Homecare Settings; Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure
Which Emerging Trends Are Reshaping The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Landscape?
Leading firms in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are concentrating on the creation of dual inhibitor therapeutic solutions for better patient outcomes and effective blood sugar control. This refers to treatments that act on two separate sodium-glucose cotransporters (SGLT1 and SGLT2) concurrently to increase effectiveness in managing diseases such as heart failure and diabetes. For example, Lexicon Pharmaceuticals Inc., a biopharmaceutical firm based in the US, received approval from the Food and Drug Administration (FDA) in May 2023 for sotagliflozin, a heart failure medication. This innovative dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-a-day tablet designed to decrease cardiovascular death, hospitalizations due to heart failure, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Key advantages include decreased renal glucose and sodium reabsorption, leading to reductions in preload and afterload, and lowered sympathetic activity.
Who Are The Global Leaders Steering The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forward?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp
Browse Through More Reports Similar to the Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2025, By The Business Research Company
Sodium Cocoyl Isethionate Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report
Sodium Reduction Ingredients Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/sodium-reduction-ingredients-global-market-report
Sodium Lauryl Ether Sulfate Sles Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
